Capabilities · Research & Development
Non-infringing process development, DSIR-approved
Mac-Chem's DSIR-approved R&D lab develops non-infringing manufacturing processes across oncology and non-oncology APIs, focused on cost efficiency, complex reaction execution, and on-time delivery.
R&D ≈ 8% of revenue · 10–12 generic molecules developed per year (company-reported)
The lab
A DSIR-approved R&D function
Mac-Chem's research and development work is carried out in a DSIR-approved R&D lab, supporting process development for both the marketed API catalog and the pipeline behind it.
What R&D does
Non-infringing process development
The R&D function is built around non-infringing process development: designing manufacturing routes that clear a molecule's technological and IP barriers rather than replicating an existing route. Alongside route design, the team targets cost efficiency through process optimization, the ability to execute complex reactions reliably, and on-time delivery against partner timelines.
Scope
Oncology and non-oncology APIs
R&D work spans both of Mac-Chem's core therapeutic areas: oncology APIs and non-oncology (general) APIs, feeding all three of the company's API segments, Oncology API, Lyophilized Bulk Sterile API, and General API.
Investment
Company-reported R&D activity
Mac-Chem reports R&D spend at approximately 8% of revenue, supporting development of 10 to 12 generic molecules per year.
-
10
Oncology candidates
-
7
Non-oncology candidates
-
17
Total pipeline molecules
The team
41 scientists, plus regulatory and project management
A technical team of 41 scientists, covering synthesis and analytics, underpins R&D and process-development work, supported by dedicated regulatory affairs and project-management functions that carry a molecule from lab-scale development through to a partner-ready dossier.
Pipeline register
17 molecules in development
Every row below is drawn live from Mac-Chem's documented API pipeline (src/data/pipeline-api.json) — not illustrative placeholder data.
-
Ribociclib
In development -
Abemaciclib
In development -
Apalutamide
In development -
Venetoclax
In development -
Upadacitinib
In development -
Ruxolitinib
In development -
Olaparib
In development -
Niraparib tosylate monohydrate
In development -
Nintedanib esylate
In development -
Ibrutinib
In development -
Parecoxib for injection
In development -
Ketoprofen for Injection
In development -
Cisatracurium
In development -
Tigecycline
In development -
Rocuronium bromide
In development -
Sugammadex
In development -
Noradrenaline bitartrate
In development